Antibacterial potential of Manuka honey against three oral bacteria in vitro by Schmidlin, Patrick R et al.








Antibacterial potential of Manuka honey against three oral bacteria in vitro
Schmidlin, Patrick R; English, Helen; Duncan, Warwick; Belibasakis, Georgios N; Thurnheer, Thomas
Abstract: Honey is an ancient natural remedy for the treatment of infected wounds. It has regained
attention in the medical profession, as it has recently been reported to have a broad-spectrum inhibitory
effect against bacteria. Data concerning Manuka honey of New Zealand origin, which is claimed to
provide additional non-peroxide antimicrobial activity (so-called standard NPA) against oral pathogens,
is still scarce. Therefore, this study aimed to screen for the antibacterial efficacy of different Manuka
honey products against S. mutans (OMZ 918), P. gingivalis (OMZ 925) and A. actinomycetemcomitans
(OMZ 299). Chlorhexidine and saline served as positive and negative controls, respectively, whereas a
Swiss multifloral honey served as control honey without intrinsic non-peroxide activity. Chlorhexidine
showed the highest inhibiting potential against all specimens tested. Manuka honey below an NPA
value of 15 showed the least bacterial growth-inhibiting potential, even less although not significantly so
than multifloral Swiss honey. Manuka honey above an NPA value of 15 showed a significantly higher
antibacterial effect compared to the other honeys tested. All Manuka honey preparations were more
effective in inhibiting the growth of P. gingivalis and A. actinomycetemcomitans, rather than S. mutans.
In conclusion, the study showed an NPA dose-dependent antibacterial efficacy of Manuka honey. Further
investigations of this natural product are now open for scrutiny.
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Introduction
Gingivitis and periodontitis are bacterial infections modified by 
systemic and environmental factors (Page & Kornman 1997). The 
main treatment target remains the effective reduction of the 
supra- and subgingival pathogenic flora, mainly by mechanical 
means. A variety of antibiotics and antiseptics have been intro-
duced as adjunct to mechanical therapy (Greenstein 2005). 
Whereas the use of systemic antibiotics is warranted in certain 
cases, it is associated with risks, notably the development of 
antibiotic resistance in various bacterial species (Bidault et al. 
2007). However, administration of subgingival and topical anti-
microbial agents as a quick and inexpensive means of support-
ing mechanical periodontal debridement is worth consideration 
(Slots 2002). Apart from well-investigated and established anti-
septics frequently used in gingivitis/periodontitis prophylaxis 
and treatment protocols like chlorhexidine or iodine, natural 
products would be a desirable alternative (Molan 2001). Among 
them, natural products such as bee honey have a great potential 
to be used as adjuncts to mechanical periodontal treatment and 
infection control. 
ABSTRACT
Honey is an ancient natural remedy for the treat-
ment of infected wounds. It has regained attention 
in the medical profession, as it has recently been 
reported to have a broad-spectrum inhibitory 
 effect against bacteria. Data concerning  Manuka 
honey of New Zealand origin, which is claimed 
to provide additional non-peroxide  antimicrobial 
 activity (so-called standard NPA) against oral 
pathogens, is still scarce.
Therefore, this study aimed to screen for the 
 antibacterial efficacy of different Manuka honey 
products against S. mutans (OMZ 918), P. gingivalis 
(OMZ 925) and A. actinomycetemcomitans 
(OMZ 299). Chlorhexidine and saline served as 
 positive and negative controls, respectively, 
whereas a Swiss multifloral honey served as con-
trol honey without intrinsic non-peroxide activity. 
Chlorhexidine showed the highest inhibiting 
 potential against all specimens tested. Manuka 
 honey below an NPA value of 15 showed the least 
bacterial growth-inhibiting potential, even less – 
although not significantly so – than multifloral 
Swiss honey. Manuka honey above an NPA value 
of 15 showed a significantly higher antibacterial 
 effect compared to the other honeys tested.  
All Manuka honey preparations were more 
 effective in inhibiting the growth of P. gingivalis 
and A.  actinomycetemcomitans, rather than 
S.  mutans.
In conclusion, the study showed an NPA dose- 
dependent antibacterial efficacy of Manuka  honey. 
Further investigations of this natural product are 
now open for scrutiny.
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Honey is an ancient remedy for the experiential treatment of 
infected wounds and has recently been “rediscovered” by the 
medical profession. It has been reported to have a broad-spec-
trum inhibitory effect against bacteria and yeasts (Allen et al. 
1991, Willix et al. 1992) and contains an enzyme that produces 
hydrogen peroxide when diluted (White et al. 1963). The impor-
tance of the additional antibacterial activity of honey is demon-
strated in several studies comparing the therapeutic effects of 
honey and sugar (Postmes 1997, Bose 1982, Somerfield 1991, 
French et al. 2005). The hydrogen peroxide concentration pro-
duced in honey activated by dilution is around 1 mmol/l (Molan 
1992), which is about 1,000 times less than in the 3% solution 
commonly used as an antiseptic (Gupta 1973). Although the 
 level of enzymatic hydrogen peroxide production in honey is 
very low, it is still effective as an antimicrobial agent and pro-
duces no harmful effects on tissue due to its excellent biocom-
patibility (Martin & Pileggi 2004, Ozan et al. 2007). However, 
most honey loses its antibacterial activity after treatment with 
catalase which eliminates hydrogen peroxide activity. 
But additional non-peroxide antibacterial factors have been 
identified. Manuka honey, in particular, demonstrates this type 
of activity. Manuka is the common name of Leptospermum sco-
parium, a tea tree from New Zealand (Lusby et al. 2002). This 
non-peroxide antibacterial effect is caused by methylglyoxal, 
found in high doses in Manuka honey (Adams et al. 2008, Mavric 
et al. 2008). The level of non-peroxide activity in Manuka honey 
is referred to by a standard NPA (Non Peroxide Activity) value, 
also trademarked in New Zealand as UMF (“Unique Manuka 
Factor”). This number refers to the equivalent percentage of 
phenol antiseptic in water, i.e. NPA 15 (or UMF 15) equates to an 
antibacterial activity greater or equal to a 15% solution (%w/v) 
of phenol/water. 
The antimicrobial potential of honey has been evaluated and 
a wide range of MIC values (minimum concentration of honey 
necessary for complete inhibition of bacterial growth) have been 
reported in studies comparing different honeys against single 
species of bacteria (French et al. 2005). However,  although there 
is evidence of its antimicrobial efficacy on non-oral pathogens, 
data concerning the specific activity of Manuka honey against 
oral pathogens is scarce (English et al. 2004). The aim of the 
present study was therefore to evaluate the antibacterial efficacy 
of different Manuka honey products against three well estab-
lished putative oral pathogens in vitro using an agar diffusion 
method as well as determinations of the minimal inhibitory 
concentrations (MIC) and minimal bactericidal concentrations 
(MBC). We hypothesized that Manuka honey would exhibit 
 superior antibacterial efficacy than other commonly consumed 
honey types, in a dose-dependent manner.
Materials and methods
Semi-liquid honey formulations were tested on Aggregatibacter 
actinomycetemcomitans (OMZ 299), Porphyromonas gingivalis 
(OMZ 925) and Streptococcus mutans (OMZ 918). For the inocu-
lum, the three strains were grown separately in growth medium 
containing fluid universal medium (FUM; Gmür & Guggenheim 
1983), supplemented with 67 mmol/l Sørensen’s buffer, final 
pH 7.2) and 0.3% glucose. Towards the end of the exponential 
growth phase the optical density of the cell suspensions was 
measured at a wavelength of 550 nm and adjusted by dilution 
with FUM to an optical density of 1.0. Columbia Blood Agar 
(CBA) without addition of blood (Becton Dickinson Microbiolo-
gy Systems, Sparks, MD, USA) was prepared according to the 
manufacturer’s instructions. The agar was kept in a water bath 
at 50°C until further use. For each strain, Petri dishes were pre-
pared by mixing 20 ml of agar with 1 ml of the corresponding 
inoculum. After hardening of the culture medium, wells mea-
suring 5 mm in diameter were punched out. These cavities were 
then filled with the different materials. The following honey 
products were tested:
a) Swiss multifloral honey (Apiary Halbheer, Rüti,  Switzerland)
b) Manuka honey NPA 5+ (Watson & Son, Masterton,  
New Zealand)
c) Manuka honey NPA 15+ (Watson & Son, Masterton,  
New Zealand)
d) Manuka honey Label “MGO 400+”, equivalent to NPA 20+ 
(Manuka Health New Zealand Ltd, Te Awamutu,  
New Zealand) 
e) Manuka honey NPA 25+ (Watson & Son, Masterton, 
New Zealand)
f) MediHoneyTM Medical Honey (Comvita® Derma Sciences 
Maidenhead, UK)
g) MediHoneyTM Gel Sheet (Comvita® Derma Sciences 
 Maidenhead, UK)
All honey preparations were maintained at 35°C for 1 hour be-
fore use to make them more flowable and then the products 
were filled in the vial to completely fill the well (Fig. 1). Chlor-
hexidine (0.2%, Kantonsapotheke, Zürich, Switzerland) and 
sterile physiologic saline served as controls (filling the well cor-
responded to 40 µl). In the case of the gel sheet, a standardized 
punch sample 4 mm was taken and placed in the well, which 
was then filled with sterile saline (40 µl). After 48 hours of an-
aerobic incubation at 37°C, the zones of inhibition were mea-
sured using a caliper. The experiments were performed in tripli-
cate. 
In addition, MIC and MBC of the best performing honey in  
the agar diffusion test were determined with liquid cultures in 
96-well flat-bottom polystyrene microtitre test plates (Milian, 
Wohlen, Switzerland) as described in details earlier (Shapiro et 
al. 1994). In short, Manuka NPA 25+ honey solutions were pre-
pared using FUM at concentrations of 50, 20, 10, 4, 2, 1, and 
0% w/v and were tested on the same three microorganisms as 
described above for the agar diffusion tests. For each bacterial 
strain one microtitre plate was used and for each dilution 
6 wells were used. Five of the latter served to determine the 
MIC, whereas the 6th well was needed for MBC determinations. 
Plates with wells containing 180 µl of growth medium (100% 
growth controls) and 180 µl of honey solution were covered 
with plastic lids and pre-reduced for 45 minutes at 37°C in  
an anaerobic incubator (Microincubator MI22NK, Scholzen 
 Microbiology Systems AG, Necker, Switzerland), then inocu-
lated with 20 µl of a bacterial culture adjusted to an optical den-
sity at 550 nm (OD550 = 0.5 ± 0.05). After 48 hours of anaerobic 
incubation at 37°C (Microincubator MI22NK), each plate was 
covered with a plastic foil (Plate Sealers, Microtec, Embrach, 
Switzerland) and vigorously shaken for 10 seconds (model 
AM 69 micro- shaker, Dynatech, Kloten, Switzerland) and 
 immediately scanned (492 nm) using an Epoch microplate 
spectrophotometer (BioTek, Luzern, Switzerland). The MIC  
was  defined as the minimal honey concentration that precluded 
growth (OD492< 0.05).
For MBC 25 µl of the corresponding honey concentrations 
used for MIC testing were withdrawn from the microtitre plate, 
stroked on Columbia Blood Agar plates (CBA) (Difco, Basing-
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stoke, Hamps, UK) and incubated anaerobically for 48 hours 
at 37°C. Bacterial growth was visually analysed using a stereo- 
microscope (Stemi 2000, Carl Zeiss, Feldbach, Switzerland). 
The MBC was defined as the minimal concentration of the 
 honey that reduced the colony-forming units/ml by 4 orders 
of magnitude relative to the 100% growth controls.
Data presentation and statistical analyses
The zones of inhibition (mm) were calculated according to the 
following formula: (D-5 mm)/2, where D represents the greatest 
extent of the diameter including the well diameter. Therefore 
the diameter of the well was subtracted. The statistical analysis 
was performed using computer software (StatView® 4.02, Aba-
cus Concepts, Berkeley, CA, USA). Results were presented in 
mean values and standard deviations. One-way ANOVA fol-
lowed by Scheffé post-hoc testing was used to determine the 
significant differences between groups. P values smaller than 
5% were considered to be statistically significant.
Results
The results of the agar diffusion test are summarized in Table 1. 
Chlorhexidine showed the highest inhibiting potential 
against all specimens tested. As expected, saline, which was 
used as a negative control, showed no antibacterial effect. Ma-
nuka honey below an NPA value of 15 showed the least bacterial 
growth-inhibiting potential, even less – although not signifi-
cantly so – than multifloral Swiss honey, which also showed a 
considerable antibacterial effect. Manuka honey above an NPA 
value of 15+ showed a significantly higher antibacterial effect 
compared to the other honeys tested, with the exception of 
MediHoney, that showed a comparable antimicrobial effect as 
Manuka honey for P. gingivalis. However, there was no or little 
Fig. 1 Preparation of the agar plates: 
After hardening of the agar plate, 
wells were punched (A) and the agar 
was sucked (B). Finally the materials 
were carefully applied to fill the 
vial (C).
Tab. I Zones of inhibition in mm (mean ± standard deviation) around the different preparations (identical superscript capitals 
 represent values which do not differ statistically significantly from each other (ANOVA, Scheffé, read vertically) with regard to  
the  bacterial strain tested)
S. mutans P. gingivalis A. actinomycetemcomitans
Multifloral honey (CH) 1.2 ± 0.1AB 3.1 ± 1.1A 3.5 ± 0.5AB
Manuka honey 5+ 0.8 ± 0.5AC 2.8 ± 0.6A 3.9 ± 0.3BC
Manuka honey 15+ 3.1 ± 0.3D 4.3 ± 0.1B 4.9 ± 0.2DE
Manuka honey 20+ 3.2 ± 0.2D 5.2 ± 0.3B 4.7 ± 0.7BCD
Manuka honey 25+ 3.7 ± 0.6D 5.6 ± 0.6B 5.8 ± 0.1F
MediHoney 2.0 ± 0.1B 5.0 ± 0.3B 5.3 ± 0.1F
MediHoney, gel sheet 0.0 ± 0.0C 2.0 ± 0.6A 2.3 ± 0.4A
Chlorhexidine 0.2% 10.3 ± 0.1E 11.8 ± 0.4C 9.7 ± 0.3G
Saline 0.0 ± 0.0C 0.0 ± 0.0D 0.0 ± 0.0H
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significant difference between the three Manuka honey samples 
with an NPA ≥ 15+, indicating an optimal effect at this NPA value. 
It is also worth noting that all Manuka honey preparations were 
more effective in inhibiting the growth of P. gingivalis and A. acti-
nomycetemcomitans, rather than S. mutans.
MIC and MBC of Manuka honey 25+ were determined, be-
cause this compound showed the best activity against all bacte-
rial strains under investigation. Since – from a practical per-
spective – honey was dissolved in fluid, dilutions instead of 
concentrations are reported. The average optical densities 
(OD492) of the tested bacteria after growth on Manuka honey 
25+ dilutions used for MIC determinations are listed in Table 2. 
The MIC for A. actinomycetemcomitans, P. gingivalis, and S. mutans 
accounted for 1:25, 1:10, and 1:5, respectively. The lowest dilu-
tion required to kill these bacteria was > 1:2 for all three bacterial 
strains. 
Discussion
This study tested the growth inhibiting effect of different Ma-
nuka honey products against three well established oral patho-
gens in vitro using an agar diffusion method. The study showed 
antibacterial efficacy, which was dose-dependent, but an NPA 
level greater than 15+ showed comparable properties, which 
were more pronounced than the control honey and – surpris-
ingly – than the MediHoney. 
In general, an NPA (non-peroxide activity) rating of 10 is 
considered the minimum for therapeutic efficacy. Our study 
supports this in finding that NPA 5+ showed no superior effect. 
Therefore, ‘ordinary’ Manuka honey has only hydrogen perox-
ide antibacterial properties, which are common to most types 
of honey, as corroborated in this study. In contrast, Manuka 
honey with an NPA of 10+ and greater has both the natural hy-
drogen peroxide antibacterial property and its own natural 
non-peroxide antibacterial properties, giving it increased anti-
bacterial potency. 
In addition, when discussing the therapeutic effects of honey, 
a difference between ‘normal’ honey (meant for alimentary 
consumption) and so-called ‘medical’ honey (approved for 
therapeutic use) has to be made. Most of the ‘normal’ honey 
products undergo heat treatment before landing on supermar-
ket shelves, which destroys the enzyme responsible for the hy-
drogen peroxide production; whereas the ‘medical’ honey is 
sterilized by gamma irradiation, which ensures persisting activ-
ity of hydrogen peroxidase (Lusby et al. 2002). In addition, anti-
microbial activity of different honeys varies considerably, even 
if gained from the same floral source. However, using this agar 
diffusion test, the differences at high concentrations were not 
considerable. The percentages of the various components de-
pend on the plant of origin and its geographic location, the sea-
son it was collected, its treatment since harvest and its age 
(Lusby et al. 2002). In this study, we used the agar diffusion 
method as well as MIC/MBC determinations. Different screen-
ing methods to determine antibacterial activity are available: 
E.g. variants of the agar diffusion method (well and disc), bio-
autographic methods (direct and indirect) and microdilution 
assay. A comparative study has found that that the well variant 
of the diffusion method was more sensitive than the disc variant 
(Valgas et al. 2007). Bioautographic and diffusion techniques, 
however, were found to have similar sensitivity. But the latter 
technique provided even more suitable conditions for the mi-
crobial growth. Therefore, the agar diffusion method may still 
offer good option to screen the antibacterial effect of natural 
products (Schmidlin Et Al. 2003). Since the antimicrobial effects 
of the Manuka honey upon single oral pathogens are confirmed 
by this study, the next step would be to validate the efficacy of 
these honey preparations on an in vitro multi-species biofilm 
model.
Despite the positive results of this study, the therapeutic us-
age of Manuka honey in periodontal pockets remains question-
able and still needs critical evaluation. Although Manuka honey 
displayed an antibacterial potential, it was still weaker than the 
control compound chlorhexidine. Therefore, the clinical useful-
ness can be questioned. However, the ongoing search and 
 evaluation of natural products is still warranted (National policy 
on traditional medicine and regulation of herbal medicines: 
 Report of a WHO global survey. World Health Organization. 
ISBN 92 4 159323 7) and Manuka one option to be considered as 
a natural antiseptic alternative, especially for patients seeking 
complementary agents and alternatives for synthetic chemicals. 
Preparation of the dressing is sticky, and handling in clinical 
situations (e.g. application into the depth of the periodontal 
pocket) will be challenging. Saliva and sulcus fluid may lead to 
quick liquefaction of the honey, and cause insufficient resting 
time in the periodontal pocket for the development of antibac-
terial effects. Honey allergy, even though very rare, can lead to 
various clinical symptoms including anaphylaxis (Karakaya & 
Fuat Kalyoncu 1999). Another factor to consider is root caries 
development. Especially when treating difficult-to-clean fur-
cation areas, honey can pose a considerable caries risk that 
should not be underestimated. However, as shown in the pres-
Tab.II Average optical densities (OD492) after growth on different concentrations of Manuka honey 25+ (n = 5).
Bacterial strains tested
Manuka honey dilution A. actinomycetemcomitans P. gingivalis S. mutans
1 :100 0.593 0.877 1.163
1 :50 0.541 0.839 1.077
1 :25 0.010* 0.790 0.952
1 :10 0.010 0.014 0.687
1 :5 0.005 0.019 0.009
1 :2 0 0 0.006
*Bold values indicate MICs
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ent study, Manuka honey even displayed an antimicrobial 
 activity against the cariogenic bacteria S. mutans. Our findings 
are corroborated by past research demonstrating activity of 
 Manuka honey against organisms in dental plaque that cause 
decay, along with inhibition of acid formation (Badet & Quero 
2011). In addition, it must be emphasized that the application 
of the honey would be indicated only after careful debridement, 
i.e. removal of plaque, which also reduces the potential risk 
of caries development, and that no long-time applications are 
possible, which also minimizes the risk of pain and hypersensi-
tivity on exposed root surfaces following contact with highly 
osmolar honey.
All these clinical aspects should be taken into consideration 
and critically assessed before proceeding further to clinical ap-
plications. Therefore, tests using an in vitro oral biofilm model 
are planned, for further validation of the antimicrobial activities 
of the Manuka honey and the demineralizing effect of this natu-
ral antibacterial compound. These studies will also focus on the 
incorporation of other natural antibacterial products (Takarada 
et al. 2004), e.g. propolis. 
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Résumé
Le miel est un ancien remède naturel pour le traitement des 
plaies infectées. En tant que produit naturel, il représente un 
intérêt pour la médecine dentaire. L’effet antibactérien du miel 
s’explique essentiellement par plusieurs mécanismes. De par sa 
forme de sucre hautement concentré, le miel agit par osmose et 
donc avec effet antibactérien. D’autre part, du peroxyde d’hy-
drogène est formé en solution aqueuse par l’action d’enzymes 
intrinsèques. D’autres mécanismes d’action antibactériens, 
sans association avec le peroxyde, ont été décrits avec le mé-
thylglyoxal, qui représente une activité métabolique connue 
sous l’abréviation de NPA (non peroxide activity): plus la valeur 
du NPA est élevée, plus actif est le mécanisme d’action anti-
bactérien. Ce NPA se trouve augmenté dans le miel de manuka 
de Nouvelle-Zélande. Toutefois, les résultats concernant l’acti-
vité antimicrobienne ici sont encore rares, surtout en ce qui 
concerne les agents pathogènes parodontaux. Le but de la pré-
sente étude était d’évaluer le potentiel antibactérien de diffé-
rents produits de miel contre Streptococcus mutans (OMZ 918), 
Porphyromonas gingivalis (OMZ 925) et Aggregatibacter actinomy-
cetemcomitans (OMZ 299) avec un test simple de dépistage de 
laboratoire. La chlorhexidine et du sérum physiologique ont  
été utilisés respectivement comme contrôle positif et négatif, 
tandis qu’un miel de fleurs suisse a servi de contrôle sans 
 aucune activité spécifique de NPA. Toutes les substances ont 
été analysées dans des plaques d’Agar pour déterminer le déve-
loppement de foyers d’inhibition de croissance bactérienne. 
Des trous ont été percés dans les plaques d’Agar contenant  
les souches bactériennes et remplis avec la préparation de miel 
spécifique en quantité standardisée. Au terme d’une période 
d’incubation appropriée, les foyers d’inhibition ont été mesu-
rés. 
La chlorhexidine a montré le potentiel inhibiteur le plus élevé 
contre toutes les bactéries testées. Le miel de manuka d’une va-
leur NPA en dessous de 15 a montré la plus faible inhibition de  
la croissance bactérienne, légèrement en dessous de l’inhibition 
mesurée du miel de fleurs suisse – bien que sans différence sta-
tistique significative. Les miels de manuka ayant une valeur NPA 
supérieure à 15 ont par contre montré des effets antibactériens 
plus élevés que tous les autres types de miel testés en ce qui 
concerne l’inhibition de P. gingivalis et A. actinomycetemcomitans. 
Par contre pour S. mutans, l’effet inhibiteur était plus faible.
Ainsi, cette étude a montré une activité antibactérienne 
dose-dépendante du miel de manuka. Toutefois, il reste à dé-
montrer dans quelle mesure l’efficacité contre la prolifération 
bactérienne de germes individuels observée dans un test de 
 laboratoire est aussi valable dans un environnement de biofilms 
complexes ou même dans des conditions in vivo.
Zusammenfassung
Honig ist ein altes Naturheilmittel im Rahmen der Behandlung 
infizierter Wunden. Als Naturprodukt ist es wieder in den Fo- 
kus der Zahnmedizin gerückt. Die antibakterielle Wirksamkeit 
von Honig kann grundsätzlich durch mehrere Mechanismen 
 erklärt werden: Einerseits wirkt Honig bereits als konzentrierte 
Zucker form osmotisch und damit antibakteriell, zum andern 
wird durch intrinsische Enzyme Wasserstoffperoxid in wäss-
riger  Lösung gebildet. Es wurden aber auch sogenannte nicht-
Peroxid- assoziierte Wirkmechanismen respektive Aktivitäten 
beschrieben, welche zum Beispiel durch Methylglyoxal in 
 Erscheinung treten. Diese Aktivität wird mit NPA abgekürzt 
(je höher der Wert, umso aktiver ist der Honig). Letztere findet 
sich vermehrt in Manukahonig aus Neuseeland. Daten bezüg-
lich der antimikrobiellen Wirksamkeit sind hierbei jedoch noch 
spärlich, vor allem im Hinblick auf parodontale Krankheits-
erreger. Daher war es das Ziel der vorliegenden Studie, das anti-
bakterielle  Potenzial verschiedener Honigprodukte gegen Strep-
tococcus mutans (OMZ 918), Porphyromonas gingivalis (OMZ 925) 
und Aggregatibacter actinomycetemcomitans (OMZ 299) in einem 
einfachen Laborscreeningverfahren zu evaluieren. Chlorhexidin 
und Kochsalzlösung dienten als Positiv- und Negativkontrollen, 
wohingegen ein herkömmlicher Schweizer Blütenhonig als 
Kontrolle ohne NPA diente. Alle Substanzen wurden in Agar 
bezüg lich Hemmhofentwicklung analysiert. Zu diesem Zweck 
wurden Löcher in die mit Bakterien versetzten Agarplatten 
 gestanzt und die Präparate darin in standardisierter Menge ein-
gebracht. Nach entsprechender Inku bationszeit wurden die 
Hemmhöfe vermessen.  
Chlorhexidin zeigte das höchste Hemmpotential gegen alle 
getesteten Bakterien. Manukahonig unter einem Wert von 
15 NPA zeigte die geringste Bakterienwachstumshemmung. 
Diese lag noch unterhalb der Bakterieninhibition des Schwei-
zer Blütenhonigs – wenngleich nicht statistisch signifikant. 
Manuka honig-Sorten über einem Wert von 15 NPA zeigten  
im Vergleich zu den anderen getesteten Honigsorten hingegen 
eine deutlich höhere antibakterielle Hemmwirkung gegen 
P. gingivalis und A. actinomycetemcomitans. Bezüglich S. mutans 
war die Wirksamkeit geringer.
Somit zeigte die Studie eine dosisabhängige antibakterielle 
Wirksamkeit von Manukahonig. Inwieweit nun diese im Labor 
festgestellte Wirksamkeit gegen ein Bakterienwachstum von 
Einzelkeimen im einfachen Agartestverfahren auch bei komple-
xen Biofilmen oder in vivo wirksam ist, muss allerdings noch 
gezeigt werden.
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